The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
This article was originally published in The Pink Sheet Daily
After two failed studies, The Medicines Co.’s rapid-acting IV antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.
You may also be interested in...
As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.
Speeding heart attack patients into the PCI lab may have blurred the timeline on their MIs and botched endpoint data, says Meanwell.